Integrity Alliance LLC. Makes New $10.29 Million Investment in Zevra Therapeutics, Inc. $ZVRA

Posted by Brenda Bartman on Nov 4th, 2026

Integrity Alliance LLC. acquired a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 938,167 shares of the company’s stock, valued at approximately $10,292,000. Integrity Alliance LLC. owned approximately 1.58% of Zevra Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $33,000. Profund Advisors LLC lifted its holdings in shares of Zevra Therapeutics by 605.6% in the third quarter. Profund Advisors LLC now owns 109,547 shares of the company’s stock valued at $1,202,000 after purchasing an additional 94,021 shares in the last quarter. State of Wyoming acquired a new position in shares of Zevra Therapeutics during the third quarter worth about $81,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Zevra Therapeutics by 15.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,835 shares of the company’s stock worth $123,000 after buying an additional 1,427 shares during the period. Finally, Sterling Capital Management LLC boosted its position in shares of Zevra Therapeutics by 2,396.6% during the third quarter. Sterling Capital Management LLC now owns 21,895 shares of the company’s stock worth $240,000 after buying an additional 21,018 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZVRA shares. Guggenheim decreased their price objective on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. Citizens Jmp boosted their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Zevra Therapeutics in a research report on Thursday, August 20th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $27.14.

View Our Latest Stock Analysis on Zevra Therapeutics

Insider Activity at Zevra Therapeutics

In other news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the transaction, the director directly owned 1,800 shares in the company, valued at approximately $20,250. The trade was a 87.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Neil McFarlane sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total value of $225,000.00. Following the transaction, the chief executive officer directly owned 417,225 shares in the company, valued at $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.70% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $10.26 on Wednesday. Zevra Therapeutics, Inc. has a 52-week low of $8.01 and a 52-week high of $15.03. The company has a market capitalization of $609.24 million, a P/E ratio of 6.39 and a beta of 1.01. The company has a 50-day simple moving average of $11.11 and a 200 day simple moving average of $10.75.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The firm had revenue of $37.76 million for the quarter, compared to the consensus estimate of $37.08 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. As a group, equities analysts forecast that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current year.

About Zevra Therapeutics

(Free Report)

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.